Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Fisher & Paykel Healthcare Corp Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$19.67 billion
P/E Ratio
158.34
Dividend Yield
1.16%
Shares Outstanding
583.98 million
Earnings per share
0.226
Dividend per share
0.38
Year To Date Return
61.03%
Earnings Yield
0.63%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Fisher & Paykel Healthcare Corp Ltd (ASX: FPH)
Latest News
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Share Market News
Here are the top 10 ASX 200 shares today
Share Gainers
Why Bank of Queensland, Fisher & Paykel, Mayne Pharma, and Medibank shares are rising
Healthcare Shares
ASX healthcare share rockets 9% on upgraded profit growth guidance
Healthcare Shares
Buy Pro Medicus and these ASX healthcare stocks now
Investing Strategies
2 soaring ASX shares that show zero signs of slowing
Broker Notes
Here's a 'shopping list' of this fundie's highest quality ASX stocks
Healthcare Shares
This ASX 200 stock just smashed 52-week highs. Is it still a buy?
Share Gainers
Here are the top 10 ASX 200 shares today
Share Market News
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Frequently Asked Questions
-
Yes, Fisher & Paykel Healthcare has historically paid two unfranked shareholder dividends a year.
-
Fisher & Paykel Healthcare generally pays its shareholder dividends in July and December.
-
Yes, Fisher & Paykel Healthcare has a dividend reinvestment plan which allows eligible shareholders in New Zealand, Australia, and the United Kingdom to reinvest all or part of their cash dividends in additional ordinary shares free of brokerage fees.
-
Yes, Fisher & Paykel Healthcare Corporation Ltd is listed on the ASX and the New Zealand Exchange.
-
Fisher & Paykel Healthcare Corporation Ltd listed on the ASX on 21 November 2001.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 26 Jun 2024 | $0.2137 | 0.00% | Final | 10 Jul 2024 |
| 05 Dec 2023 | $0.0318 | 0.00% | Supplemental | 18 Dec 2023 |
| 05 Dec 2023 | $0.1800 | 0.00% | Interim | 18 Dec 2023 |
| 26 Jun 2023 | $0.0406 | 0.00% | Supplemental | 07 Jul 2023 |
| 26 Jun 2023 | $0.2117 | 0.00% | Interim | 07 Jul 2023 |
| 08 Dec 2022 | $0.0309 | 0.00% | Supplemental | 21 Dec 2022 |
| 08 Dec 2022 | $0.1645 | 0.00% | Interim | 21 Dec 2022 |
| 22 Jun 2022 | $0.0397 | 0.00% | Supplemental | 06 Jul 2022 |
| 22 Jun 2022 | $0.2029 | 0.00% | Final | 06 Jul 2022 |
| 02 Dec 2021 | $0.0300 | 0.00% | Supplemental | 15 Dec 2021 |
| 02 Dec 2021 | $0.1784 | 0.00% | Interim | 15 Dec 2021 |
| 24 Jun 2021 | $0.0388 | 0.00% | Supplemental | 07 Jul 2021 |
| 24 Jun 2021 | $0.2046 | 0.00% | Final | 07 Jul 2021 |
| 03 Dec 2020 | $0.0282 | 0.00% | Supplemental | 16 Dec 2020 |
| 03 Dec 2020 | $0.1510 | 0.00% | Interim | 16 Dec 2020 |
| 06 Jul 2020 | $0.0274 | 0.00% | Supplemental | 17 Jul 2020 |
| 06 Jul 2020 | $0.1463 | 0.00% | Final | 17 Jul 2020 |
| 06 Dec 2019 | $0.0212 | 0.00% | Supplemental | 19 Dec 2019 |
| 06 Dec 2019 | $0.1148 | 0.00% | Interim | 19 Dec 2019 |
| 13 Jun 2019 | $0.1287 | 0.00% | Final | 05 Jul 2019 |
| 07 Dec 2018 | $0.0172 | 0.00% | Supplemental | 21 Dec 2018 |
| 07 Dec 2018 | $0.0921 | 0.00% | Interim | 21 Dec 2018 |
| 21 Jun 2018 | $0.0221 | 0.00% | Supplemental | 06 Jul 2018 |
| 21 Jun 2018 | $0.1151 | 0.00% | Final | 06 Jul 2018 |
| 05 Dec 2017 | $0.0154 | 0.00% | Supplemental | 20 Dec 2017 |
| 05 Dec 2017 | $0.7802 | 0.00% | Interim | 20 Dec 2017 |
| 15 Jun 2017 | $0.0199 | 0.00% | Supplemental | 07 Jul 2017 |
| 15 Jun 2017 | $0.1074 | 0.00% | Final | 07 Jul 2017 |
| 06 Dec 2016 | $0.0789 | 0.00% | Interim | 21 Dec 2016 |
| 16 Jun 2016 | $0.0955 | 0.00% | Final | 08 Jul 2016 |
| 09 Dec 2015 | $0.0629 | 0.00% | Interim | 23 Dec 2015 |
| 17 Jun 2015 | $0.0710 | 0.00% | Final | 10 Jul 2015 |
| 03 Dec 2014 | $0.0537 | 0.00% | Interim | 19 Dec 2014 |
| 18 Jun 2014 | $0.0650 | 0.00% | Final | 04 Jul 2014 |
| 04 Dec 2013 | $0.0491 | 0.00% | Interim | 19 Dec 2013 |
| 19 Jun 2013 | $0.0586 | 0.00% | Final | 05 Jul 2013 |
| 29 Nov 2012 | $0.0426 | 0.00% | Interim | 14 Dec 2012 |
| 20 Jun 2012 | $0.0550 | 0.00% | Final | 06 Jul 2012 |
| 30 Nov 2011 | $0.0413 | 0.00% | Interim | 16 Dec 2011 |
| 22 Jun 2011 | $0.0534 | 0.00% | Final | 08 Jul 2011 |
| 01 Dec 2010 | $0.0418 | 0.00% | Interim | 17 Dec 2010 |
| 28 Jun 2010 | $0.0000 | 0.00% | Final | 09 Jul 2010 |
| 10 Dec 2009 | $0.0301 | 0.00% | Interim | 18 Dec 2009 |
| 22 Jun 2009 | $0.0476 | 0.00% | Final | 06 Jul 2009 |
| 04 Dec 2008 | $0.0095 | 0.00% | Supplemental | 12 Dec 2008 |
| 04 Dec 2008 | $0.0000 | 0.00% | Interim | 12 Dec 2008 |
| 19 Jun 2008 | $0.0062 | 0.00% | Supplemental | 27 Jun 2008 |
| 19 Jun 2008 | $0.0700 | 0.00% | Final | 27 Jun 2008 |
| 06 Dec 2007 | $0.0095 | 0.00% | Supplemental | 14 Dec 2007 |
| 06 Dec 2007 | $0.0473 | 0.00% | Interim | 14 Dec 2007 |
| 21 Jun 2007 | $0.0124 | 0.00% | Supplemental | 29 Jun 2007 |
| 21 Jun 2007 | $0.0700 | 0.00% | Final | 29 Jun 2007 |
| 23 Nov 2006 | $0.0095 | 0.00% | Supplemental | 01 Dec 2006 |
| 23 Nov 2006 | $0.0540 | 0.00% | Interim | 01 Dec 2006 |
| 19 Jun 2006 | $0.0124 | 0.00% | Supplemental | 28 Jun 2006 |
| 19 Jun 2006 | $0.0700 | 0.00% | Final | 28 Jun 2006 |
| 02 Dec 2005 | $0.0095 | 0.00% | Supplemental | 09 Dec 2005 |
| 02 Dec 2005 | $0.0540 | 0.00% | Interim | 09 Dec 2005 |
| 08 Jun 2005 | $0.0102 | 0.00% | Supplemental | 17 Jun 2005 |
| 08 Jun 2005 | $0.0580 | 0.00% | Final | 17 Jun 2005 |
| 24 Nov 2004 | $0.0088 | 0.00% | Supplemental | 03 Dec 2004 |
| 24 Nov 2004 | $0.0500 | 0.00% | Interim | 03 Dec 2004 |
| 14 Jun 2004 | $0.0494 | 0.00% | Supplemental | 18 Jun 2004 |
| 14 Jun 2004 | $0.2800 | 0.00% | Final | 18 Jun 2004 |
FPH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Fisher & Paykel Healthcare Corp Ltd
Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) is among the world's major designers and manufacturers of respiratory devices. These include products and systems covering in-hospital respiratory care, acute care, and the treatment of obstructive sleep apnea.
The New Zealand-based company earns around 42% of its revenue from the US market and around 30% in Europe. Its hospital products account for about 65% of its revenue with its at-home sleep apnea devices and other respiratory aids accounting for the rest.
Fisher & Paykel invests more than 10% of its operating revenue into its own research and development and has thousands of patents and pending applications. The company has manufacturing facilities in both New Zealand and Mexico.
FPH Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Nov 2024 | $33.56 | $-0.70 | -2.04% | 251,610 | $34.23 | $34.23 | $33.49 |
| 19 Nov 2024 | $34.26 | $0.07 | 0.20% | 286,381 | $34.22 | $34.56 | $33.93 |
| 18 Nov 2024 | $34.19 | $0.68 | 2.03% | 374,576 | $33.55 | $34.35 | $33.35 |
| 15 Nov 2024 | $33.51 | $-0.34 | -1.00% | 203,744 | $34.27 | $34.27 | $33.31 |
| 14 Nov 2024 | $33.85 | $-0.10 | -0.29% | 299,822 | $34.01 | $34.02 | $33.41 |
| 13 Nov 2024 | $33.95 | $-0.26 | -0.76% | 281,299 | $34.17 | $34.25 | $33.36 |
| 12 Nov 2024 | $34.21 | $0.13 | 0.38% | 326,780 | $34.08 | $34.57 | $33.99 |
| 11 Nov 2024 | $34.08 | $-0.09 | -0.26% | 172,196 | $34.05 | $34.27 | $33.81 |
| 08 Nov 2024 | $34.17 | $0.95 | 2.86% | 231,885 | $33.47 | $34.17 | $33.31 |
| 07 Nov 2024 | $33.22 | $0.27 | 0.82% | 403,716 | $32.89 | $33.22 | $32.35 |
| 06 Nov 2024 | $32.95 | $-0.05 | -0.15% | 442,480 | $33.33 | $33.38 | $32.61 |
| 05 Nov 2024 | $33.00 | $-0.06 | -0.18% | 223,537 | $32.96 | $33.31 | $32.60 |
| 04 Nov 2024 | $33.06 | $0.09 | 0.27% | 572,177 | $33.00 | $33.18 | $32.62 |
| 01 Nov 2024 | $32.97 | $0.16 | 0.49% | 271,604 | $32.63 | $32.98 | $32.21 |
| 31 Oct 2024 | $32.81 | $0.12 | 0.37% | 464,067 | $32.63 | $32.92 | $32.50 |
| 30 Oct 2024 | $32.69 | $-0.08 | -0.24% | 236,248 | $32.69 | $32.79 | $32.21 |
| 29 Oct 2024 | $32.77 | $-0.96 | -2.85% | 1,923,765 | $33.70 | $33.92 | $32.77 |
| 28 Oct 2024 | $33.73 | $0.43 | 1.29% | 139,926 | $33.40 | $33.86 | $33.40 |
| 25 Oct 2024 | $33.30 | $-0.40 | -1.19% | 284,760 | $33.66 | $34.02 | $33.30 |
| 24 Oct 2024 | $33.70 | $0.01 | 0.03% | 336,716 | $33.93 | $33.93 | $33.36 |
| 23 Oct 2024 | $33.69 | $0.03 | 0.09% | 293,758 | $33.48 | $33.69 | $33.23 |
| 22 Oct 2024 | $33.66 | $-0.34 | -1.00% | 469,012 | $33.73 | $34.16 | $33.64 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 12 Sep 2024 | Graham McLean | Buy | 800 | $27,932 |
As advised by the company. Purchase of Ordinary Shares, As per announcement on 17-09-2024
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Michael Grenfell Daniell | Non-Executive Director | Nov 2001 |
Mr Daniell was General Manager of Fisher & Paykel's medical division from 1990 to 2001 and previously held various technical management and product design roles within the company. Mike is a director of Cochlear Limited, Tait International Limited and the Medical Research Commercialisation Fund. Michael was named a Knight Companion of the New Zealand Order of Merit in June 2021. He is Chair of Quality, Safety & Regulatory Committee.
|
| Mr Lewis George Gradon | Chief Executive OfficerManaging Director | Apr 2016 |
Mr Gradon spent 15 years as Senior Vice President of Products and Technology, and six years as General Manager of Research and Development. During his 41-year tenure with Fisher & Paykel Healthcare, he has held various engineering positions overseeing the development of our range of products as well the development of manufacturing, quality, intellectual property, supply chain and clinical research functions.
|
| Mr Neville Mitchell | Non-Executive DirectorNon-Executive Chairman | Nov 2018 |
Mr Mitchell was Chief Financial Officer and Company Secretary of Cochlear between 1995 and 2017. He is a director of Sonic Healthcare and Sigma Healthcare, and is a former director of The Board of Tax, Southeastern Sydney Local Health District, Osprey Medical and Sirtex Medical. Previously, he served on the New South Wales Medical Devices Fund, was Chairman of the Group of 100, and Chairman, Standing Committee (Accounting and Auditing) for the Australian Securities and Investments Commission. He is Chair of Risk Committee and member of Quality, Safety & Regulatory Committee.
|
| Dr Lisa Margaret McIntyre | Non-Executive Director | Oct 2021 |
Dr McIntyre is a director of The University of Sydney, Studiosity, Nanosonics and Baymatob. She has previously been a director of a range of health entities, including those in healthcare insurance, clinical service delivery and medical research and innovation. Lisa spent 20 years as a senior strategy partner with LEK Consulting providing advice to companies in North America, Asia and Australia. She is member of the Risk Committee.
|
| Mr Andrew Mark Cross | Non-Executive Director | Oct 2024 |
Mr Cross has governance experience in other listed companies. He currently chairs the board of Chorus, where he has been a director since 2016. He is also a director of Xero, and a board member and Investment Committee Chair of Accident Compensation Corporation (ACC). He is a former chair of Milford Asset Management and a former director of Z Energy, Genesis Energy and Argosy Property. Previously, Mr Cross held executive positions with Deutsche Bank in London and Sydney, as well as Lloyds Corporate Finance/Southpac Corporation in Australia and New Zealand. In those roles, he was an advisor to businesses across a range of sectors including healthcare, utilities, energy, industrials and chemicals.
|
| Ms Philippa (Pip) Mary Greenwood | Non-Executive Director | Jun 2017 |
Ms Greenwood is the Chair of Westpac New Zealand Limited and also Chair of The a2 Milk Company Limited. Pip was a partner at Russell McVeagh between 2001 and 2019 and served as the firm's Board Chair. She has advised on many corporate transactions. Pip also served as a member of the New Zealand Takeovers Panel from 2007 to 2011. She is member of the Risk Committee.
|
| Mr Graham McLean | Non-Executive Director | Oct 2023 |
Mr McLean is a director and CEO of CleanSpace Technology and the Chair of Universal Biosensors. Graham previously spent 16 years as an executive at medical device manufacturer Stryker Corporation, most recently as President of the Asia Pacific region situated in Hong Kong and Singapore. Prior to joining Stryker, Graham had finance, audit and commercial positions at Lion Nathan, McVitie's and Unilever. He is member of the Risk Committee.
|
| Dr Cather Simpson | Non-Executive Director | Jun 2022 |
Dr Simpson is a professor of physics and chemical sciences at the University of Auckland and a partner at Pacific Channel, with expertise in lasers and photonics. She is a director of the International Society for Optics & Photonics (SPIE) and the Dodd-Walls Centre for Photonic & Quantum Technologies, and CEO of Orbis Diagnostics. In 2010, Cather established the Photon Factory at the University of Auckland, from which she co-founded three hard-tech start-ups, including Engender Technologies, where she served as Chief Science Officer from 2011 to 2021. She is Member of Quality, Safety & Regulatory Committee.
|
| Mr Marcus James Driller | Company SecretaryVice President - Corporate |
-
|
|
| Ms Raelene Leonard | Company Secretary |
-
|
|
| Lyndal York | Chief Financial Officer |
-
|
|
| Andy Niccol | Chief Operating Officer |
-
|
|
| Raelene Leonard | Company Secretary |
-
|
|
| Marcus James Driller | Company SecretaryVice President - Corporate |
-
|
|
| Raelene Leonard | General Counsel and Company Secretary |
-
|
|
| Malena Ortiz | General Director of Mexico Operations |
-
|
|
| Desh Edirisuriya | General Manager of New Zealand Operations |
-
|
|
| Nicholas Fourie | Vice President of Information & Communication Technology |
-
|
|
| Andrew Somervell | Vice President of Products & Technology |
-
|
|
| Brian Schultz | Vice President of Quality Safety & Regulatory Affairs |
-
|
|
| Justin Callahan | Vice President of Sales & Marketing |
-
|
|
| Jonti Rhodes | Vice President of Supply Chain Facilities & Sustainability |
-
|
|
| Winston Fong | Vice President of Surgical Technologies |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Nominees (New Zealand) Limited R601127393 | 83,534,220 | 14.30% |
| HSBC Nominees (New Zealand) Limited R601127385 | 51,836,973 | 8.88% |
| JPMorgan Nominees Australia Pty Limited | 48,653,179 | 8.33% |
| HSBC Custody Nominees (Australia) Limited | 48,028,803 | 8.22% |
| JPMorgan Chase Bank | 38,408,220 | 6.58% |
| BNP Paribas Nominees NZ Limited | 33,584,164 | 5.75% |
| Citicorp Nominees Pty Limited | 28,309,187 | 4.85% |
| Citibank Nominees (Nz) Ltd | 28,202,203 | 4.83% |
| Custodial Services Limited | 20,719,852 | 3.55% |
| TEA Custodians Limited | 19,546,919 | 3.35% |
| New Zealand Superannuation Fund Nominees Limited | 16,302,952 | 2.79% |
| Accident Compensation Corporation | 9,671,894 | 1.66% |
| Premier Nominees Limited | 7,427,317 | 1.27% |
| National Nominees Limited | 7,257,801 | 1.24% |
| FNZ Custodians Limited | 7,171,404 | 1.23% |
| New Zealand Depository Nominee | 6,377,776 | 1.09% |
| JBWere (NZ) Nominees Limited | 5,500,973 | 0.94% |
| Public Trust | 5,287,041 | 0.91% |
| PT Booster Investments Nominees Limited | 4,157,341 | 0.71% |
| New Zealand Permanent Trustees Limited | 4,099,423 | 0.70% |
